Archives

Overall survival, but not progression-free survival, improved with tremelimumab plus durvalumab versus sorafenib for unresectable HCC

Overall survival, progression-free survival prolonged in those receiving durvalumab versus placebo in addition to gemcitabine and cisplatin

Establishing a genetic diagnosis for patients with unexplained infantile or childhood-onset epilepsy can help individualize treatment

Delays tied to more seizures prior to diagnosis, conversion to motor-type seizures, potentially preventable injuries

Event-free survival prolonged with axi-cel versus standard care as second-line therapy for refractory, relapsed disease

Screening protocol could identify candidates for neuromodulation therapies who could skip a formal in-person psychological assessment

Machine learning used to generate risk score based on clinical data and measurements from stress cardiovascular magnetic resonance

Measurements of cardiac performance with transthoracic echocardiography may reveal subclinical cardiac dysfunction

Two-year overall survival 72 percent for those starting with N/I, 52 percent for those starting with dabrafenib/trametinib

In post-COVID-19 peak period in 2020, CT volume still down for cancer screening and initial workup with inconsistent recovery for active cancer